WO2023042158 - METHODS OF DETERMINING AND PROVIDING CLINICALLY MEANINGFUL IMPROVEMENTS ON PATIENT REPORTED OUTCOMES IN ANOREXIA / CACHEXIA PATIENTS
National phase entry:
Publication Number
WO/2023/042158
Publication Date
23.03.2023
International Application No.
PCT/IB2022/058788
International Filing Date
16.09.2022
Title **
[English]
METHODS OF DETERMINING AND PROVIDING CLINICALLY MEANINGFUL IMPROVEMENTS ON PATIENT REPORTED OUTCOMES IN ANOREXIA / CACHEXIA PATIENTS
[French]
PROCÉDÉS POUR DÉTERMINER ET APPORTER DES AMÉLIORATIONS CLINIQUEMENT SIGNIFICATIVES À DES RÉSULTATS RAPPORTÉS AU PATIENT CHEZ DES PATIENTS ATTEINTS D'ANOREXIE/CACHEXIE
Applicants **
HELSINN HEALTHCARE SA
Via Pian Scairolo 9
CH-6912 Lugano/Pazzallo, CH
Inventors
PALMESINO, Elena
Via Coremmo, 3A
CH-6900 Lugano, CH
CHESSARI, Salvatore
c/o Helsinn Healthcare SA
Via Pian Scairolo 9
CH-6912 Lugano/Pazzallo, CH
GIORGINO, Ruben
Oberwilerstrasse, 51 C
4123 Allschwil, CH
Priority Data
63/245,270
17.09.2021
US
63/357,007
30.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1057 | |
| EPO | Filing, Examination | 4664 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 4510 |
Total: 11429 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Uses of anamorelin for improving patient reported outcomes in anorexia / cachexia patients, particularly based on patient populations who benefit from such use, and methods for defining and providing clinically meaningful treatment effects.[French]
L'invention concerne des utilisations de l'anamoréline pour améliorer les résultats rapportés au patient chez des patients atteints d'anorexie/cachexie, en particulier sur la base de populations de patients qui bénéficient d'une telle utilisation, et des procédés pour définir et procurer des effets de traitement cliniquement significatifs.